The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...

Research focuses on chronic myeloid leukemia with the goal of creating a new therapy for patients Study funded by Robert & Lynda Carter Altman Family Foundation Research Fund LOS ANGELES--(BUSINESS ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

Please provide your email address to receive an email when new articles are posted on . Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.

If the name of leukemia specialist Jorge Cortes, MD, appears any more often in PubMed, they’ll need to name a wing after him. Jorge Cortes, MD Over 30 years, Cortes has led or co-authored hundreds of ...

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...